{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:45:29Z","timestamp":1766400329337,"version":"3.40.5"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The objective of this study was to describe real-world health-related quality of life (HRQoL) and treatment satisfaction of ibrutinib-treated patients with CLL compared to a reference group. This study was completed in two parts. The first portion (Norming Study) was a US online survey conducted to serve as a reference population. The Norming Study included a total of 139 patients with CLL, excluding those treated with ibrutinib: 64 were treatment naive (Tx naive), 36 were 1<jats:sup>st<\/jats:sup> line (1L), and 38 were in or had completed \u22652 lines (2L+) patients with CLL. The second portion (CLL Ibrutinib Study) included 1L and 2L+ ibrutinib patients with CLL treated for \u22656 months in which 118 patients (1L n = 88 and 2L+ n = 30) completed the study. Respondents completed demographic and clinical information and the following HRQoL surveys: (Short Form-12v2<jats:sup>\u00ae<\/jats:sup> Health Survey [SF-12v2], Functional Assessment of Cancer Therapy-General [FACT-G], FACT-Leukemia [FACT-Leu] Functional Assessment of Chronic Illness Therapy [FACIT]-Fatigue, and Cancer Therapy Satisfaction Questionnaire [CTSQ]). Higher scores indicate better HRQoL\/treatment satisfaction. Differences in effect sizes between the two samples at the group level were calculated using Hedges\u2019 g. Medium to large positive effects were seen in the CLL Ibrutinib group on several measures compared to the Reference Study groups. The FACT-G total score was 89.2\u00b111.1 for CLL Ibrutinib Study patients compared to 75.8\u00b122.6 CLL Norming Tx na\u00efve patients, 61.3\u00b121.8 in 1L, and 61.7\u00b120.7 in 2L+. Similar trends were seen with FACT-Leu total score and FACIT-Fatigue. CLL Ibrutinib Study patients scored higher on all CTSQ domain scores compared to the CLL Norming patients treated with other CLL therapies. We found that Ibrutinib-treatment had better HRQoL and treatment satisfaction compared to patients receiving other therapies, irrespective of line of therapy.<\/jats:p>","DOI":"10.1371\/journal.pone.0270291","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T17:39:47Z","timestamp":1665077987000},"page":"e0270291","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-444X","authenticated-orcid":true,"given":"Kathleen L.","family":"Deering","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murali","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Harshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremiah","family":"Trudeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline Claudia","family":"Barrientos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"pone.0270291.ref001","unstructured":"American Cancer Society. Cancer facts & figures 2022. 2022 [Internet]. [cited 2022 Apr 10]. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2022.html"},{"key":"pone.0270291.ref002","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results (SEER). Cancer stat facts: Leukemia \u2010 Chronic Lymphocytic Leukemia (CLL) [Internet]. [cited 2022 Apr 10]. https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html"},{"issue":"25","key":"pone.0270291.ref003","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"M Hallek","year":"2018","journal-title":"Blood"},{"issue":"12","key":"pone.0270291.ref004","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1007\/s11136-015-1039-y","article-title":"Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study","volume":"24","author":"KM Holtzer-Goor","year":"2015","journal-title":"Qual Life Res"},{"issue":"5","key":"pone.0270291.ref005","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/01.mjt.0000104489.93653.0f","article-title":"Chronic lymphocytic leukemia: economic burden and quality of life literature review","volume":"12","author":"JM Stephens","year":"2005","journal-title":"Am J Ther"},{"issue":"5","key":"pone.0270291.ref006","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40273-015-0367-7","article-title":"Economic burden and quality-of-life effects of chronic lymphocytic leukemia: a systematic review of the literature","volume":"34","author":"S Frey","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"pone.0270291.ref007","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/03007995.2020.1784120","article-title":"Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents","volume":"36","author":"C Waweru","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"pone.0270291.ref008","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00277-014-2161-6","article-title":"Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL\/SLL in the Netherlands","volume":"94","author":"EC van den Broek","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"pone.0270291.ref009","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2004.00233.x","article-title":"Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr","volume":"72","author":"B Holzner","year":"2004","journal-title":"Eur J Haematol"},{"issue":"3","key":"pone.0270291.ref010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.genhosppsych.2007.01.014","article-title":"Depression, anxiety and quality of life in a chronic lymphocytic leukemia cohort","volume":"29","author":"TT Levin","year":"2007","journal-title":"Gen Hosp Psychiatry"},{"issue":"9","key":"pone.0270291.ref011","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1080\/10428194.2017.1416364","article-title":"Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma in the HELIOS study","volume":"59","author":"P Cramer","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"pone.0270291.ref012","unstructured":"Maruish, M. E. (Ed.). (2012). User\u2019s manual for the SF-12v2 Health Survey (3rd ed.). Lincoln, RI: QualityMetric Incorporated."},{"issue":"3","key":"pone.0270291.ref013","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"DF Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"8","key":"pone.0270291.ref014","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jval.2012.08.2210","article-title":"Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy\u2013Leukemia (FACT-Leu) questionnaire","volume":"15","author":"D Cella","year":"2012","journal-title":"Value Heal"},{"issue":"5","key":"pone.0270291.ref015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.pmrj.2010.04.017","article-title":"Building a Measure of Fatigue: The Functional Assessment of Chronic Illness Therapy Fatigue Scale","volume":"2","author":"E Smith","year":"2010","journal-title":"PM R"},{"issue":"9","key":"pone.0270291.ref016","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00520-010-0971-1","article-title":"Self-reported fatigue: One dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire","volume":"19","author":"D Cella","year":"2011","journal-title":"Support Care Cancer"},{"issue":"Suppl 1","key":"pone.0270291.ref017","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1111\/j.1524-4733.2005.00073.x","article-title":"Development of the cancer therapy satisfaction questionnaire: item generation and content validity testing","volume":"8","author":"L Abetz","year":"2005","journal-title":"Value Health"},{"issue":"4","key":"pone.0270291.ref018","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1524-4733.2007.00310.x","article-title":"Psychometric validation of the cancer therapy satisfaction questionnaire","volume":"11","author":"PC Trask","year":"2008","journal-title":"Value Heal"},{"issue":"2","key":"pone.0270291.ref019","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3102\/10769986006002107","article-title":"Distribution Theory for Glass\u2019s estimator of effect size and related estimators","volume":"6","author":"L V. Hedges","year":"1981","journal-title":"J Educ Stat"},{"key":"pone.0270291.ref020","volume-title":"Statistical power analysis for the behavioral sciences","author":"J. Cohen","year":"1988","edition":"2"},{"issue":"18","key":"pone.0270291.ref021","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.ejca.2006.08.016","article-title":"Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research","volume":"42","author":"B Holzner","year":"2006","journal-title":"Eur J Cancer"},{"issue":"2","key":"pone.0270291.ref022","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0163278705275341","article-title":"General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G)","volume":"28","author":"PS Brucker","year":"2005","journal-title":"Eval Heal Prof"},{"issue":"2","key":"pone.0270291.ref023","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06791.x","article-title":"Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients","volume":"139","author":"TD Shanafelt","year":"2007","journal-title":"Br J Haematol"},{"key":"pone.0270291.ref024","unstructured":"Primary A, Unit C, Languages A, Method DC, Izquierdo A, Gabriela P, et al. SF-12v2 Health Survey, Third Edition. Vol. 9, Health (San Francisco). 2005. 9 p."},{"issue":"6","key":"pone.0270291.ref025","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/ejh.13503","article-title":"Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ-C30 and QLQ-CLL17 questionnaire","volume":"105","author":"P Youron","year":"2020","journal-title":"Eur J Haematol"},{"issue":"3","key":"pone.0270291.ref026","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2015.0530","article-title":"Patient-reported outcomes in cancer drug development and US regulatory review: perspectives from industry, the Food and Drug Administration, and the patient","volume":"1","author":"E Basch","year":"2015","journal-title":"JAMA Oncol"},{"issue":"4","key":"pone.0270291.ref027","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/14737167.2013.814957","article-title":"US FDA patient-reported outcome guidance: great expectations and unintended consequences","volume":"13","author":"S Fehnel","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"9","key":"pone.0270291.ref028","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1093\/annonc\/mdv283","article-title":"Planning and reporting of quality-of-life outcomes in cancer trials","volume":"26","author":"S Schandelmaier","year":"2015","journal-title":"Ann Oncol"},{"issue":"21","key":"pone.0270291.ref029","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMp2009027","article-title":"They call us and we go","volume":"382","author":"S. Koven","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0270291.ref030","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.clml.2018.08.007","article-title":"Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATE study of ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"18","author":"JC Barrientos","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"pone.0270291.ref031","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study","volume":"17","author":"A Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"pone.0270291.ref032","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-133798","article-title":"Real-world prognostic biomarker testing, treatment patterns and dosing among 1461 patients (pts) with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) from the informCLL prospective observational registry","volume":"136","author":"AR Mato","year":"2020","journal-title":"Blood"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0270291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T17:40:18Z","timestamp":1665078018000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0270291"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0270291","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,10,6]]}}}